News

Bristol Myers posts better-than-expected second quarter results on strength of top sellers
Bristol Myers Squibb posted much better-than-expected second-quarter results on Wednesday on strong sales of its most established and best-selling brands, blood thinner Eliquis and cancer treatments Opdivo and Revlimid.
Bristol Myers Beats Earnings Expectations. It’s Still Optimistic About New Schizophrenia Drug.
Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs expire in the coming years.
Bristol Myers Squibb Cuts Full-Year Adjusted View, But Raises Revenue Expectations
Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a charge related to its BioNTech partnership.
Bristol Myers Squibb Reports Second Quarter Financial Results for 2025
Bristol Myers Squibb (NYSE: BMY) today reported second quarter 2025 financial results. Visit the company’s Investor Relations website at to view the detailed second quarter 2025 earnings press release and investor presentation.
What to expect from Bristol-Myers Squibb's Q2 earnings?
Bristol-Myers Squibb Company (NYSE:BMY) is scheduled to announce Q2 earnings results on July 31st, before markets open. Analysts expect the company’s key metrics to see a year-on-year decline. EPS is estimated to see a 45.
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors
This was the stock's fifth consecutive day of losses.
Bristol Myers Squibb: A Stock with Potential Amid Challenges
Explore the exciting world of Bristol Meyers Squibb (NYSE: BMY) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
How Will Bristol Myers Squibb Stock React To Its Upcoming Earnings?
Over the past five years, BMY's one-day stock returns following earnings announcements have been evenly split:
Bristol Myers Squibb put volume heavy and directionally bearish
B earish flow noted in Bristol Myers Squibb with 9,747 puts trading, or 1.5x expected. Most active are 8/1 weekly 46 puts and Aug-25 47 calls, with total volume in those strikes n
Bristol Myers, Bain Capital form a new biopharmaceutical company
Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...
Goldman Sachs Maintains a Hold on Bristol-Myers Squibb (BMY)
Bristol-Myers Squibb Company (NYSE:BMY) is one of the top low volatility healthcare stocks to buy now. On July 24, Goldman ...
PharmExec1d
Bristol Myers Squibb Spins Out Immunology Assets into New Company Backed by Bain Capital
The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...
BioPharma Dive1d
Bain leads $300M investment in startup built on Bristol Myers immune drugs
Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...
Bristol Myers, Bain Capital form new company to develop immunology drugs
Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...
Fierce Biotech2d
BMS hands 5 autoimmune drugs to new spinout backed by $300M in Bain-led funding
Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...
BioPharma Dive5d
Bristol Myers shuffles its executive ranks with new CMO
AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...